Shattuck Labs, Inc.

NASDAQ:STTK

Biotechnology

Healthcare
$4.47 +2.33%

+$0.11 today

Market cap
$455.24M
Beta
1.09
P/E (TTM)
-10.9
EPS (TTM)
-$0.44
52W Low $0.71High $8.33

Volume 2.08M

Average 0.69M

STTK Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Shattuck Labs, Inc.NASDAQ: STTK

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $4.6M rose 2.9% year over year, ahead of the -6.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 6.6% from the prior quarter. Over 3 fiscal years it compounded at -4.3% a year.

Context

  • Selling, general & admin amounted to 1723.5% of revenue in FY2025, up 1390.0 pp from a year earlier.
  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 6 analysts of $1.26M (-92.7%) for the fiscal year ending Dec 2026, a slowdown from the -9.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.6M+6.6% QoQ
Last fiscal yearDec 2025
$17.24M-9.7% YoY
LTMMar 2026
$17.37M-6.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.9%-100.0%-102.9 pp
1 year-9.7%-92.7%-83.0 pp
3-year CAGR-4.3%-47.3%-43.0 pp
5-year CAGR-13.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
17.24M USD
Year-over-year change
-9.7%
4-year CAGR
-2.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How STTK compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -6.9% is the 9th highest of 10, against a peer median of +45.3%.
  • Selling, general & admin amounts to 1736.5% of revenue for STTK, versus a peer median of 40.4%.
STTK Competitors
Selling, General & Admin for STTK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$3.07B USD+22461.6%+0.7%—
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$153.2M USD-3.3%+13.5%40.4%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$72.24M USD-5.3%-7.5%31.8%
FTHFaeth Therapeutics, Inc.LTM Jun 2026$34.02M USD+184.4%-13.9%—
CBIOCrescent Biopharma, Inc.LTM Mar 2026$29.66M USD+100.0%+10.0%249.6%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥21.46M CNY+128.2%-71.8%—
STTKShattuck Labs, Inc.LTM Mar 2026$17.37M USD-6.9%-4.3%1736.5%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$16.29M USD+45.3%-0.9%—
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$15.86M USD-38.3%-16.4%—
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$10.4M USD+38.2%+6.9%—
Peer median (excluding STTK) —+45.3%-0.9%40.4%

Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.02M652K1.66M5.72M1M
Cost of Revenue1.38M82.2M4.04M4.89M0
Gross Profit28.64M(81.55M)(2.39M)827K1M
Gross Margin95.4%-12507.2%-143.9%14.5%100.0%
Research & Development56.56M82.9M74.31M67.21M35.27M
Selling, General & Admin18.72M19.68M19.3M19.08M17.24M
Operating Expenses73.91M21.78M89.57M81.39M52.51M
Depreciation & Amortization1.38M3.07M4.04M3.83M3.69M
EBITDA(43.59M)(98.87M)(83.26M)(71.58M)(45.12M)
EBITDA Margin-145.2%-15164.4%-5024.5%-1251.2%-4512.1%
Operating Income(45.27M)(103.33M)(91.96M)(80.57M)(51.51M)
Operating Margin-150.8%-15848.0%-5549.6%-1408.3%-5150.8%
Interest Income625K1.59M4.67M5.17M2.7M
Interest Expense00000
Other Income / Expenses295K1.38M4.66M5.16M2.7M
Income Before Tax(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Pre-Tax Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
Income Tax Expense00000
Net Income(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Net Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
EPS (Basic)(1.07)(2.41)(2.05)(1.49)(0.70)
EPS (Diluted)(1.07)(2.41)(2.05)(1.49)(0.70)
Weighted Avg Shares42.03M42.38M42.6M50.76M69.58M
Weighted Avg Shares (Diluted)42.03M42.38M42.6M50.76M69.58M

Shattuck Labs, Inc.

NASDAQ:STTK

Intrinsic Alpha fair value

Locked

Current Price

$4.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.